Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.92
  • Today's Change0.00 / 0.00%
  • Shares traded206.99k
  • 1 Year change-35.03%
  • Beta1.5025
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

  • Revenue in USD (TTM)50.70m
  • Net income in USD-44.82m
  • Incorporated2020
  • Employees207.00
  • Location
    AVITA Medical Inc28159 Avenue Stanford, Suite 220VALENCIA 91355United StatesUSA
  • Phone+1 (661) 367-9170
  • Websitehttps://www.avitamedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Fennec Pharmaceuticals Inc44.95m2.84m192.95m36.00194.7064.0367.854.290.03660.03661.620.11120.98781.157.52--6.25-73.437.37-84.3296.19--6.33-383.286.721.840.9087--1,284.50--32.34------
Galectin Therapeutics Inc0.00-44.78m194.38m14.00---------0.7373-0.73730.00-1.140.00----0.00-177.94-92.08-373.85-121.97-----------10.247.25-------15.26------
Kodiak Sciences Inc0.00-232.75m196.48m107.00--0.8145-----4.44-4.440.004.590.00----0.00-43.30-31.73-47.44-33.61------------0.00------21.97--134.76--
Elevation Oncology Inc0.00-39.35m197.24m29.00--2.46-----1.03-1.030.001.470.00----0.00-42.35---46.30-------------12.500.2889------51.93------
Zevra Therapeutics Inc28.01m-50.90m199.22m65.00--4.08--7.11-1.34-1.340.75131.170.2172--3.47430,876.90-39.48-32.11-47.94-39.8951.11---181.75-128.42----0.4929--170.26---72.00--69.75--
bluebird bio Inc21.73m-91.17m199.87m323.00--0.505--9.20-0.7446-0.74460.21392.080.0383----67,263.16-16.08-33.02-21.50-37.14-10.0819.44-419.62-4,044.311.42--0.00---1.77-36.7152.62---26.66--
Trevi Therapeutics Inc0.00-33.57m200.04m25.00--2.71-----0.338-0.3380.001.050.00----0.00-34.47-47.39-38.08-54.41------------0.0017------0.2984---2.81--
Lineage Cell Therapeutics Inc8.00m-23.66m200.13m75.00--2.76--25.01-0.1344-0.13440.04550.38360.0722--57.16106,706.70-21.32-19.53-24.82-22.5991.8889.13-295.30-370.88----0.0018---39.1612.3918.22---27.16--
Veru Inc13.48m-35.82m200.55m189.00--4.44--14.88-0.3465-0.34650.12670.30890.18981.423.8671,318.68-50.43-42.91-76.84-54.4134.1372.41-265.74-104.964.22--0.177---58.590.5394-10.84--67.39--
CervoMed Inc8.08m-4.15m201.06m8.0047.6528.17--24.870.51130.51131.740.86480.6124----1,010,531.00-31.45-53.67-38.42-58.89-----51.36-949.54----0.00------86.07------
Atossa Therapeutics Inc0.00-30.09m201.74m10.00--2.22-----0.2386-0.23860.000.72640.00----0.00-27.39-29.97-28.80-32.55------------0.00-------11.62---33.90--
AVITA Medical Inc50.70m-44.82m204.33m207.00--6.27--4.03-1.76-1.761.991.260.53361.488.39244,913.00-47.18---53.79--85.43---88.41--6.64-19.610.5591--45.68---32.69------
Werewolf Therapeutics Inc16.22m-41.58m212.06m46.00--1.80--13.07-1.09-1.090.43432.720.087--4.61345,127.70-22.31---25.22-------256.33------0.2511--21.60--30.56------
Puma Biotechnology Inc226.63m15.38m212.73m185.0013.704.177.900.93870.32190.32194.741.061.1010.958.131,225,016.007.49-12.2111.65-20.5373.4478.786.78-11.791.382.570.6624--3.34-1.251,079,450.00--83.41--
Data as of May 17 2024. Currency figures normalised to AVITA Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

21.56%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20241.62m6.32%
The Vanguard Group, Inc.as of 31 Mar 20241.36m5.28%
Geode Capital Management LLCas of 31 Dec 2023528.66k2.06%
SSgA Funds Management, Inc.as of 31 Dec 2023500.31k1.95%
AWM Investment Co., Inc.as of 31 Dec 2023496.95k1.93%
Pura Vida Investments LLCas of 31 Dec 2023361.10k1.41%
Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023220.67k0.86%
Driehaus Capital Management LLCas of 31 Dec 2023209.26k0.81%
CenterBook Partners LPas of 31 Mar 2024145.35k0.57%
Columbia Management Investment Advisers LLCas of 31 Dec 202398.68k0.38%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.